Stockscreener 앱 받기
144.48
1.18%
1.69
시간 외 거래:
144.68
0.20
+0.14%
전일 마감가:
$142.79
열려 있는:
$144.25
하루 거래량:
2.05M
Relative Volume:
0.85
시가총액:
$31.19B
수익:
$606.42M
순이익/손실:
$-1.28B
주가수익비율:
-22.56
EPS:
-6.403
순현금흐름:
$-997.58M
1주 성능:
-6.67%
1개월 성능:
+0.38%
6개월 성능:
-12.84%
1년 성능:
+98.87%
1일 변동 폭
$143.28
$145.62
1주일 범위
$142.03
$156.64
52주 변동 폭
$63.81
$212.75
Insmed Inc Stock (INSM) Company Profile
명칭
Insmed Inc
전화
908-977-9900
주소
700 US HIGHWAY 202/206, BRIDGEWATER, NJ
Compare INSM vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
INSM
Insmed Inc
|
144.48 | 31.19B | 606.42M | -1.28B | -997.58M | -6.403 |
VRTX
Vertex Pharmaceuticals Inc
|
441.20 | 112.22B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
750.57 | 79.35B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
849.04 | 52.80B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
309.66 | 41.32B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
323.87 | 35.95B | 5.36B | 287.73M | 924.18M | 2.5229 |
Insmed Inc Stock (INSM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-10 | 개시 | Raymond James | Outperform |
| 2026-03-30 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2026-03-16 | 재개 | Jefferies | Buy |
| 2026-01-28 | 개시 | Barclays | Overweight |
| 2026-01-23 | 개시 | Roth Capital | Buy |
| 2025-12-19 | 재개 | Truist | Buy |
| 2025-12-04 | 개시 | Rothschild & Co Redburn | Buy |
| 2025-10-28 | 재개 | Cantor Fitzgerald | Overweight |
| 2025-10-20 | 개시 | Wells Fargo | Overweight |
| 2025-08-20 | 개시 | William Blair | Outperform |
| 2025-08-13 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2025-05-13 | 개시 | Jefferies | Buy |
| 2025-02-25 | 개시 | RBC Capital Mkts | Outperform |
| 2024-04-23 | 개시 | Truist | Buy |
| 2024-02-15 | 개시 | Wolfe Research | Outperform |
| 2023-12-08 | 개시 | Wells Fargo | Overweight |
| 2023-11-20 | 재개 | JP Morgan | Overweight |
| 2023-07-26 | 개시 | Guggenheim | Buy |
| 2022-12-09 | 개시 | Mizuho | Buy |
| 2022-12-07 | 개시 | Barclays | Overweight |
| 2022-11-18 | 개시 | BofA Securities | Buy |
| 2022-04-27 | 개시 | Goldman | Buy |
| 2021-12-06 | 개시 | JP Morgan | Overweight |
| 2021-10-19 | 재개 | Monness Crespi & Hardt | Buy |
| 2021-10-19 | 재개 | Morgan Stanley | Overweight |
| 2021-10-08 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2020-12-17 | 개시 | Berenberg | Buy |
| 2020-10-12 | 재개 | Stifel | Buy |
| 2019-09-03 | 개시 | Goldman | Buy |
| 2019-04-09 | 재확인 | H.C. Wainwright | Buy |
| 2019-02-15 | 업그레이드 | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-01-17 | 업그레이드 | Goldman | Neutral → Buy |
| 2019-01-02 | 개시 | Canaccord Genuity | Buy |
| 2018-08-06 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2018-07-23 | 개시 | Goldman | Neutral |
| 2018-04-23 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2018-03-21 | 개시 | Morgan Stanley | Overweight |
| 2018-01-18 | 개시 | Credit Suisse | Neutral |
| 2017-09-05 | 재확인 | Evercore ISI | Outperform |
| 2017-08-17 | 개시 | Evercore ISI | Outperform |
| 2017-07-11 | 개시 | Robert W. Baird | Outperform |
| 2016-03-15 | 개시 | Stifel | Buy |
| 2015-11-09 | 다운그레이드 | UBS | Buy → Neutral |
| 2015-10-06 | 재확인 | H.C. Wainwright | Buy |
| 2015-06-09 | 개시 | Citigroup | Neutral |
| 2014-03-26 | 재확인 | HC Wainwright | Buy |
모두보기
Insmed Inc 주식(INSM)의 최신 뉴스
INSM Reiterates by Roth Capital -- Price Target Maintained at $2 - GuruFocus
Insmed chair and CEO William Lewis sells $1.54m in stock - Investing.com
Insider Selling: Insmed (NASDAQ:INSM) CEO Sells 10,699 Shares of Stock - MarketBeat
INSMED (INSM) CEO exercises options and sells 10,699 shares under 10b5-1 plan - Stock Titan
Roth Mkm Reaffirms "Buy" Rating for Insmed (NASDAQ:INSM) - MarketBeat
Roth MKM Maintains Insmed(INSM.US) With Buy Rating, Maintains Target Price $212 - 富途牛牛
William Lewis lists INSM share sales (NASDAQ: INSM) in Form 144 filing - Stock Titan
Guggenheim raises Insmed stock price target to $230 on Arikayce By Investing.com - Investing.com Canada
Guggenheim Maintains Insmed(INSM.US) With Buy Rating, Raises Target Price to $230 - Moomoo
Insmed, Inc. (NASDAQ:INSM) Short Interest Update - MarketBeat
Insmed (INSM) soars 5.5%: Is further upside left in the stock? - MSN
Insmed Inc stock (US4576693075): Is brensocatib approval the real test for rare disease growth? - AD HOC NEWS
Sumitomo Mitsui Trust Group Inc. Purchases Shares of 435,442 Insmed, Inc. $INSM - MarketBeat
INSM Maintained by RBC Capital -- Price Target Raised to $216 - GuruFocus
Insmed Sees Favorable Physician Feedback on Brinsupri, RBC Capital Markets Says - Moomoo
Oak Ridge Investments LLC Trims Position in Insmed, Inc. $INSM - MarketBeat
RBC Raises Price Target on Insmed to $216 From $212, Keeps Outperform Rating - marketscreener.com
RBC Capital Maintains Insmed(INSM.US) With Buy Rating, Raises Target Price to $216 - Moomoo
RBC Capital raises Insmed stock price target on Brinsupri outlook By Investing.com - Investing.com Canada
INSM Stock Price, Quote & Chart | INSMED INC (NASDAQ:INSM) - ChartMill
EBIT per share of Insmed Incorporated – BX:IM8N - TradingView — Track All Markets
Institution Moves: What are the future prospects of Insmed Incorporated2026 Market Mood & Risk Managed Investment Signals - baoquankhu1.vn
US Stocks Recap: Is URTY a cyclical or defensive stockGap Up & Verified Swing Trading Watchlist - baoquankhu1.vn
Risk Analysis: Is Insmed Incorporated stock a buy or sell2026 Trade Ideas & Reliable Momentum Entry Alerts - baoquankhu1.vn
Insmed (INSM): Top QQQ Stock to Buy Now - Yahoo Finance
Insmed Achieves $280 Million Trading Volume, Secures Leading Market Position Despite Positive Analyst Ratings and Clinical Challenges - Bitget
Here Are Friday’s Top Wall Street Analyst Research Calls: Autodesk, Delek US Holdings, Insmed, Nike, Nutanix, ServiceNow, Shake Shack, Southern Copper, Veeva Systems, and More - 24/7 Wall St.
What is HC Wainwright's Estimate for Insmed FY2027 Earnings? - MarketBeat
Is It Too Late To Consider Insmed (INSM) After A 146% One Year Surge? - Yahoo Finance
Insmed (INSM) poised for 2026 upside with potential $1.3B Arikayce sales boost, Roth/MKM initiates buy - MSN
Non Tuberculous Mycobacterial Infections Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | Insmed, AN2 Therapeutics, Mannkind Corp., Spero Therapeutics, Savara Pharmaceuticals - Barchart.com
FRANKLIN GROWTH OPPORTUNITIES FUND's Insmed Inc(INSM) Holding History - GuruFocus
Insmed (INSM) Halts Brensocatib R&D After Trial Setback - GuruFocus
Insmed chair and CEO William Lewis sells $1.75 million in stock - Investing.com
Insmed chair and CEO William Lewis sells $1.75 million in stock By Investing.com - Investing.com South Africa
Insmed Insider Sold Shares Worth $1,746,336, According to a Recent SEC Filing - Moomoo
Insmed (INSM) CEO sells shares, exercises options under 10b5-1 plan - Stock Titan
Trial Failure in the Skin Does Not Dent Insmed Drug’s Potential in the Lungs - MedCity News
Insmed Incorporated (INSM): Billionaire Stan Druckenmiller Trims Stake - Yahoo Finance
Interstitial Lung Disease Market to Witness Accelerated Growth at a CAGR of 8.7% During the Forecast Period (2026–2036) Due to the Launch of Emerging Therapies | DelveInsight - GlobeNewswire Inc.
Insmed Ends Brinsupri Development in Skin Disease Post Study Failure - Yahoo Finance
Insmed Drug Misses Primary Goal, Program Axed - Benzinga
Insmed freezes Brinsupri’s HS programme on Phase II failure - Yahoo Finance
Mizuho Trims Price Target on Insmed to $202 From $206, Keeps Outperform Rating - marketscreener.com
Insmed drops skin disorder candidate after mid-stage trial setback - Seeking Alpha
Insmed drops HS program for Brinsupri after Phase IIb miss - The Pharma Letter
Insmed stock falls after failed hidradenitis suppurativa trial By Investing.com - Investing.com South Africa
Insmed Discontinues Brensocatib HS Program After Phase 2b CEDAR Study Fails to Meet Endpoints - Minichart
AVIP AB Mid Cap Core Portfolio's Insmed Inc(INSM) Holding History - GuruFocus
INSM Stock Dips In Extended Trading After Experimental Skin Disease Drug Fails In Study - Stocktwits
Insmed (INSM) Maintains Buy Rating Despite Trial Setback - GuruFocus
Insmed Inc (INSM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.43%
0.99%
자본화:
|
볼륨(24시간):